For All The Latest Medical News, Health News, Research News, COVID-19 News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Cardiology News, Epigenetic News, Cancer News, Doctor News, Hospital News
Source: Thailand Medical News Sep 02, 2019 5 years, 3 months, 3 weeks, 7 hours, 27 minutes ago
Biobeat, an Israeli firm has been granted clearance by the US FDA for the company’s wrist watch and patch that measure blood oxygenation, heart rate, and blood pressure. Biobeat is the first blood pressure monitor in the world that does not rely on a traditional cuff allows for long-term monitoring of blood pressure, particularly in patients who have difficulty keeping track of their health parameters on their own. Moreover, it can help to identify abnormal blood pressure in situations when a cuff-based meter is not appropriate or simply unavailable.
Arik Ben Ishay, Founder and CEO of Biobeat told Thailand Medical “This is the global first cuffless blood pressure solution to be cleared by the US FDA—no more need for an inflating cuff. This clearance opens tremendous opportunities for remote monitoring of vital signs of patients and we are excited that we can now also offer this in the US market and soon in Europe and also Asia.”
The Biobeat devices are intended for use in clinics, hospitals, long-term care facilities, as well as by independent patients at home.The product is user friendly and easy to use.
The underlying technology within the Biobeat devices is based on reflective plethysmography, an optical technique that is normally used to detect blood volume changes within tissues. A number of LED light sources emit various wavelengths of light into the tissue, while an algorithm analyzes the reflected light that returns. Thanks to the new signal processing system that the team built, they can effectively clean out most of the background noise in the signal and obtain the relevant data hiding within. The device is highly accurate and even more so when compared with certain